U.S. markets closed
  • S&P 500

    3,819.72
    -50.57 (-1.31%)
     
  • Dow 30

    31,270.09
    -121.43 (-0.39%)
     
  • Nasdaq

    12,997.75
    -361.04 (-2.70%)
     
  • Russell 2000

    2,207.79
    -23.72 (-1.06%)
     
  • Crude Oil

    60.73
    -0.55 (-0.90%)
     
  • Gold

    1,708.10
    -7.70 (-0.45%)
     
  • Silver

    26.12
    -0.26 (-0.99%)
     
  • EUR/USD

    1.2058
    -0.0009 (-0.07%)
     
  • 10-Yr Bond

    1.4700
    +0.0550 (+3.89%)
     
  • GBP/USD

    1.3933
    -0.0020 (-0.14%)
     
  • USD/JPY

    107.0200
    +0.0180 (+0.02%)
     
  • BTC-USD

    50,395.01
    +2,500.30 (+5.22%)
     
  • CMC Crypto 200

    1,014.06
    +25.96 (+2.63%)
     
  • FTSE 100

    6,675.47
    +61.72 (+0.93%)
     
  • Nikkei 225

    29,559.10
    +150.93 (+0.51%)
     

Solid Biosciences gene therapy trial put on hold by FDA

  • Oops!
    Something went wrong.
    Please try again later.

Nov 12 (Reuters) - Solid Biosciences Inc said on Tuesday the U.S. Food and Drug Administration has put on hold a trial testing its gene therapy for a muscle-wasting disorder.

Last month one of the six patients with Duchenne muscular dystrophy dosed with the company's drug, SGT-001, experienced a serious side effect that was deemed related to the treatment, the company said. (Reporting by Tamara Mathias in Bengaluru; Editing by Sriraj Kalluvila)